# Validation, Digitized

November 2024









#### Safe Harbour Statement

This presentation contains forward-looking statements, including statements regarding Kneat's future financial outlook and financial performance, market growth, the release dates for and benefits from the use of Kneat's solutions, our strategies, and general business conditions. Any forward-looking statements contained in this presentation are based upon Kneat's historical performance and its current plans, estimates and expectations and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Kneat's expectations as of the date in this presentation. Subsequent events may cause these expectations to change, and Kneat disclaims any obligation to update the forward-looking statements in the future.

These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including (i) unexpected changes in business and economic conditions, including the global financial and capital markets; (ii) our inability to continually develop technologically advanced products; (iii) the inability of our products and services to gain market acceptance; (iv) our failure to protect our intellectual property; (v) unauthorized disclosures and breaches of security data; (vi) changes in interest and currency exchange rates; (vii) changes in operating revenues and costs; (viii) political or economic instability, either globally or in the countries in which we operate; (ix) competitive factors; (x) availability of external financing at reasonable rates or at all; (xi) our expected use of the net proceeds from the IPF Facility, our public equity financings completed in February and October 2024, and/or any future offering; (xii) the anticipated effects of the IPF Facility, our public equity financings completed in February and October 2024, and/or any future offering on our business and operations.

Further information on potential risks that could affect actual results will be included in other filings Kneat makes on www.sedarplus.com.



Providing a SaaS platform for quality management, Kneat is a compelling investment opportunity, with:

- Market leadership in life sciences validation
- High customer and revenue retention
- Strong organic growth via land and expand and new wins
- Secular support, as regulated companies seek to automate
- Improving margins, as SaaS revenue growth outpaces Services revenue and operating expenses
- Proven, founder-led executive team
- Quality-focused culture



Kneat's Data-Centered Platform Modernizes Quality Management Compliance



With Kneat, any regulated company can be confident they are developing, manufacturing and delivering their products to the highest safety standard.

**Eddie Ryan** 

CEO & Co-Founder, Kneat



#### What is Validation?

- Validation is a subset of Quality, and consists of testing, documenting and proving compliance.
- Healthcare companies **must test every system**, piece of equipment, process, manufacturing line, etc.
- Test results must be captured, documented to a high standard, approved and available for regulatory audit for many years to come.
- If the testing is not adequate, the data not trustworthy and robustly documented, then the company is out of compliance.



# High Customer ROI through Digitization

#### The paper-based pain:

- Time-, labor- and carbon-intensive
- Susceptible to data integrity issues
- Susceptible to non-compliance
- Volumes of paper documents to manage

#### How we address:

- 1st integrated, end-to-end digital platform
- Real-time data capture and visibility
- Data- and document-focused
- Easy to use

#### **RESULTS: Quality, Compliance and Speed**

- Real-time compliance and audit ready
- Eliminate data integrity issues
- Instant global collaboration and data visibility
- Efficiency and reduced schedules
- Higher quality, reduced risk





#### **Validation** includes:

- ✓ Document Management
- ✓ Analytical Instrument Validation
- ✓ Method Validation
- ✓ Commissioning and Qualification
- Drawing Management
- ✓ Utility and Facility Validation

- ✓ Equipment Validation
- ✓ Cold Chain Validation
- ✓ Electronic Logbook Management
- ✓ Process Validation
- Computer System Validation (CSV)
- ✓ Cleaning Validation

# Expansive Market Opportunity for eValidation...and beyond

Today's TAM: eVal within Life

Sciences >\$2B ARR

Medium-term TAM: eVal +

Adjacent Quality Solutions within

Life Sciences: >\$7B

Life Sciences =
Pharmaceutical, Med
Devices, Chemical,
Health & Personal
Care, Diagnostics

Life Sciences eVal + Adjacent Quality Solutions beyond eVal within Life Sciences

Life Sciences + Food &
Beverage + Aerospace &
Defense +
Transportation

Longer-term TAM: Quality Solutions for Life Sciences +

New Verticals: >\$15B

Source: D&B Hoovers; adjacent quality solutions are detailed in Kneat's Annual Information Filing dated 21 February 2024. All dollar amounts are in USD.



# Top 20 Global Pharmaceutical Companies – Most Use Kneat










































By 2022 revenue; Source: Drug Discovery & Development.

This image contains company names, product names, trade names, trademarks, and service marks of other organizations, all of which are the property of their respective owners.

# **Example of a Tier-One Land & Expand**


6 MONTHS 6 MONTHS **24-48 MONTHS** LAND AND EXPAND STRATEGY DRIVING SAAS REVENUE GROWTH \$400K \$ 200K \$100K Initial process Expansion Add new process and sites Global roll-out – multiple processes to all sites deployed at 1st to new site 138% Net Revenue Retention in 2023

## **Go-to-Market and Growth Vectors**



\$60

# Annual Recurring Revenue (ARR) ARR continues to climb





# Gross margin expands as revenue mix shifts to SaaS

